Alemtuzumab (LEMTRADA), a humanized monoclonal antibody directed against CD52, is another agent that has recently been implicated as a cause of DI-TMA with an immune-mediated mechanism resulting in significant deficiency of ADAMTS13 (ie, secondary TTP) [9, 10]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.